Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 18/20 | 0.78 |
| ▸ | PLA2G10 | O15496 | 7/20 | 0.78 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.78 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 0.78 |
| ▸ | PLA2G5 | P39877 | 5/20 | 0.78 |
| ▸ | PLA2G2F | Q9BZM2 | 4/20 | 0.78 |
| ▸ | PLA2G2D | Q9UNK4 | 4/20 | 0.78 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.78 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.78 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.78 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.78 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5710672 | 0.92 | PLA2G2A (0.76) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710595 | 0.92 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710622 | 0.91 | PLA2G2A (0.75) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib SCHEMBL26726 | 0.88 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib SCHEMBL29358982 | 0.88 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710585 | 0.87 | PLA2G2A (0.78) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib Methyl SCHEMBL29378302 | 0.87 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| Varespladib Methyl SCHEMBL25678 | 0.87 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710593 | 0.86 | PLA2G2A (0.76) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 | |
| SCHEMBL5710588 | 0.86 | PLA2G2A (0.76) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1220839-B1 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-12-06 | — | — | EP | claimed |
| US-6939890-B2 | Antiinflammatory agents; sepsis shock; rheumatic disorders | ELI LILLY AND COMPANY (US) | 2005-09-06 | — | — | US | claimed |
| EP-1220839-A2 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-07-10 | — | — | EP | claimed |
| WO-2001021587-A2 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-03-29 | — | — | WO | claimed |
| EP-1220839-B1 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-12-06 | — | — | EP | disclosed |
| US-6939890-B2 | Antiinflammatory agents; sepsis shock; rheumatic disorders | ELI LILLY AND COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-6831095-B1 | Treatment of rheumatoid arthritis | ELI LILLY AND COMPANY | 2004-12-14 | — | — | US | disclosed |
| US-20040029948-A1 | Novel sPLA2 inhibitors | HARPER RICHARD WALTZ (US) | 2004-02-12 | — | — | US | disclosed |
| EP-1220839-A2 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001021587-A2 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029948-A1 | Novel sPLA2 inhibitors | PLA2G12A, PLA2G4A, PLAAT2 | PLA2G2A 17/4885PLA2G10 11/4885PLA2G1B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.